2006流感报告 - Influenza Report

More documents

Recommendations

Info

Phone: +27 21 938 9347 Fax: + 27 21 938 9361 snjk@sun.ac.za / skorsman@theotokos.co.za Gustavo Reyes-Terán, M.D. INER Servicio de Infectología Calzada de Tlalpan #4502 Colonia Seccion XVI CP. 14080 Mexico, D. F. Phone: +52 55 5666-7985 reyesteran@iner.gob.mx Matthias Stoll, M.D., Ph.D. Abt. Klinische Immunologie Zentrum Innere Medizin der Medizinischen Hochschule Carl-Neuberg-Straße 1 D 30625 Hannover Phone: +49 511 532 3637 Fax: +49 511 532 5324 stoll.matthias@mh-hannover.de Ortrud Werner, M.D. Friedrich Loeffler Institute Federal Research Institute for Animal Health OIE National Reference Laboratoy for Avian <strong>Influenza</strong> Boddenblick 5a D – 17493 Greifswald – Insel Riems Tel: +49 38351 7152 Fax: + 49 38351 7226 ortrud.werner@fli.bund.de Contributors 9 Gert van Zyl, M.D. Specialist: Medical Virology, NHLS Tygerberg, Coastal Branch Faculty of Health Sciences, Tygerberg Campus PO Box 19063, Tygerberg 7505, SOUTH AFRICA Tel: + 27 21 938 9691 Fax: + 27 21 938 9361 E-mail: guvz@sun.ac.za
主审主译编译人员秦鄂德祝庆余秦成峰翻译人员(以汉语拼音排序) 封面设计贝祝春李晓峰李靖林磊罗渊姜涛康小平秦成峰尉雁熊伟曹晓飞
Page 2 and 3: 2006 流感报告 INFLUENZA REPORT
Page 4 and 5: 原著序三十年前,传染病似
Page 8 and 9: 目录第1章流感 2006 1 1.
Page 10 and 11: 第一章流感 2006 Bernd Sebasti
Page 12 and 13: 死亡。大于65岁、小于两岁
Page 14 and 15: 流感大流行的一个标志就
Page 16 and 17: 非洲。最近的研究显示,目
Page 18 and 19: 和多器官功能衰竭是死亡
Page 20 and 21: 图1-4.在MDCK细胞(绿色)中生
Page 22 and 23: 在途径是存在 (Stevens 2006)
Page 24 and 25: 苗组成的推荐。对于野生
Page 26 and 27: 6 个月左右的时间才能生产
Page 28 and 29: 已健全了疫苗生产的程序:
Page 30 and 31: 300 万份抗病毒药物的储存
Page 32 and 33: 内科医师、救火队员、警
Page 34 and 35: http://www.cdc.gov/ncidod/EID/vol10
Page 36 and 37: influenza season-- ew York City. MM
Page 38 and 39: containing an emerginginfluenza pan
Page 40 and 41: susceptibility network position sta
Page 42 and 43: http://www.pubmedcentral.gov/articl
Page 44 and 45: http://www.who.int/entity/bulletin/
Page 46 and 47: 86. Neirynck S, Deroo T, Saelens X,
Page 48 and 49: 103. Reid AH, Fanning TG, Hultin JV
Page 50 and 51: 118. Taubenberger JK, Reid AH, Lour
Page 52 and 53: 131. WHO 2005. The Writing Committe
Page 54 and 55: 147. Winkle S. Kulturgeschichte der
Page 56 and 57:
然而,近来禽流感已经受到
Page 58 and 59:
1997 新南威尔士 (澳大利
Page 60 and 61:
胞表面的子代病毒。该功
Page 62 and 63:
由于病毒中 RNA 依赖的 RNA
Page 64 and 65:
3 高致病性禽流感的致病机
Page 66 and 67:
赖于病毒株和宿主的种类
Page 68 and 69:
在工业化的家禽养殖基地
Page 70 and 71:
� 急性中毒 � 急性禽霍
Page 72 and 73:
毒诊断的必要条件。目前,
Page 74 and 75:
病毒可无限期的保存。Ito
Page 76 and 77:
表 2-3 人类感染禽流感病毒
Page 78 and 79:
这些动物出现严重的病症
Page 80 and 81:
初秋,临近的蒙古、哈萨克
Page 82 and 83:
不但捕杀了所有被感染和
Page 84 and 85:
相反,当疫苗病毒表达与野
Page 86 and 87:
然而,在关注亚洲 H5N1 病毒
Page 88 and 89:
in Thailand. Virology 2005; Sep 26;
Page 90 and 91:
in Italy (1999-2000) in intensively
Page 92 and 93:
y avian H5 and H7 subtypes. Vaccine
Page 94 and 95:
Abstract:http://amedeo.com/lit.php?
Page 96 and 97:
59. Guo Y, Wang M, Kawaoka Y, Gorma
Page 98 and 99:
avian influenza A virus from an avi
Page 100 and 101:
f.domestica). Vet Pathol 2006; in p
Page 102 and 103:
103. Li SQ, Orlich M, Rott R. Gener
Page 104 and 105:
mammals. J Virol 2005; 79: 11788-80
Page 106 and 107:
http://amedeo.com/lit.php?id=145750
Page 108 and 109:
143. Perdue ML, Garcia M, Senne D,
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Abstract: http://amedeo.com/lit.php
Page 116 and 117:
anchoring of avian influenza virus
Page 118 and 119:
http://www.who.int/csr/disease/avia
Page 120 and 121:
第三章人类流感病毒 Lutz G
Page 122 and 123:
有活性的 RNA-RNA 聚合酶是
Page 124 and 125:
当病毒颗粒被细胞摄取、
Page 126 and 127:
感染剂量单位为 100-1000 个
Page 128 and 129:
第四章致病机理与免疫学
Page 130 and 131:
图 4-1. 流感病毒进入呼吸
Page 132 and 133:
图4-2:甲型流感病毒的复制
Page 134 and 135:
问题的核心是主要局限于
Page 136 and 137:
如通过蛋白激酶 R 启动半
Page 138 and 139:
2004),但病毒复制的时间则
Page 140 and 141:
胞免疫球蛋白高变区编码
Page 142 and 143:
毒特异性 CD8 记忆 T 细胞的
Page 144 and 145:
from aerosol inhalation. Proc Soc E
Page 146 and 147:
10224-10228. 26. Guillot L, Le Goff
Page 148 and 149:
Airway hyperreactivity and peripher
Page 150 and 151:
patients in Vietnam. N Engl J Med 2
Page 152 and 153:
第五章流行预案 Gustavo Reye
Page 154 and 155:
由于 H5N1 抗原新、对人类
Page 156 and 157:
3.1 监督机制监督机制被定
Page 158 and 159:
流行期疫苗使用计划应包
Page 160 and 161:
作者 c 及相关工作人员 a
Page 162 and 163:
3.8 战略实施最重要的因素
Page 164 and 165:
医务人员应使用高效面罩(N
Page 166 and 167:
5 结论流感大流行可引起
Page 168 and 169:
Bull World Health Organ 2004; 82:31
Page 170 and 171:
in 10 patients in Vietnam. N Engl J
Page 172 and 173:
pandemic. Neth J Med 2005; 63: 337-
Page 174 and 175:
第六章疫苗 Stephen Korsman
Page 176 and 177:
为 2006 年南半球冬季流感
Page 178 and 179:
1. 3. 2 活病毒疫苗采用鼻
Page 180 and 181:
抗体反应是衡量疫苗免疫
Page 182 and 183:
L-传播给高危人群的可能性
Page 184 and 185:
治疗如果导致发热则有雷
Page 186 and 187:
流感疫苗的FDA网址为 http://
Page 188 and 189:
2004);当时一些公司收购疫
Page 190 and 191:
命名为“模拟疫苗”。模
Page 192 and 193:
个病毒株可降低 1µg 的剂
Page 194 and 195:
� World Health Organisation (WHO)
Page 196 and 197:
development of influenza vaccines w
Page 198 and 199:
2005; 352: 1044-6 http://amedeo.com
Page 200 and 201:
49. Pachucki CT, Pappas SA, Fuller
Page 202 and 203:
2005; 352: 1044-6 http://amedeo.com
Page 204 and 205:
Page 206 and 207:
1.2.1 病人管理由于用昂贵
Page 208 and 209:
时检测两种型别并辨别它
Page 210 and 211:
2.3.1 血凝抑制试验(HI) 血凝
Page 212 and 213:
3 流感样疾病的鉴别诊断 -1
Page 214 and 215:
这些方法的敏感性相对较
Page 216 and 217:
samples? J Clin Microbiol 2004; 42:
Page 218 and 219:
第八章临床表现 Christian Ho
Page 220 and 221:
耳:中耳炎粘膜:充血颈部
Page 222 and 223:
在慢性呼吸道发病机制中
Page 224 and 225:
阴性者(Skiest 2001,Fine 2001)。
Page 226 and 227:
参考文献 1. Agyeman P, Duppenth
Page 228 and 229:
a residential facility in New York
Page 230 and 231:
Med 2000; 160: 3243-7. 36. Morishim
Page 232 and 233:
第九章治疗和预防 C. Hoffma
Page 234 and 235:
是奥塞米韦主要的副作用,
Page 236 and 237:
类模型中,这些病毒遗传上
Page 238 and 239:
的儿童,第一次接种流感疫
Page 240 and 241:
2.3.5 妊娠: 只有在确认了以
Page 242 and 243:
人强烈要求而担任了护理
Page 244 and 245:
2. Aoki FY, Macleod MD, Paggiaro P,
Page 246 and 247:
of influenza A and B: systematic re
Page 248 and 249:
imantadine. Antimicrob Agents Chemo
Page 250 and 251:
complications and hospitalizations.
Page 252 and 253:
2000; 160: 3243-7. Abstract: http:/
Page 254 and 255:
70. Tamiflu (package insert). Gilea
Page 256 and 257:
Influenza A/(H5N1) Reported to WHO.
Page 258 and 259:
韦是通过对唾液酸类似物
Page 260 and 261:
使用奥塞米韦,因为一般认
Page 262 and 263:
1.5.3 特定的患者群体一项
Page 264 and 265:
体外研究已发现了奥塞米
Page 266 and 267:
药物分类: 神经氨酸酶抑制
Page 268 and 269:
inhibitor oseltamivir in influenza
Page 270 and 271:
1240-6. Abstract: http://amedeo.com
Page 272 and 273:
29.Kawai N, Ikematsu H, Iwaki N, et
Page 274 and 275:
43.McCullers JA. Effect of antivira
Page 276 and 277:
Kingdom. Eur J Health Econ 2005; 6:
Page 278 and 279:
infection in humans. N Engl J Med 2
Page 280 and 281:
2.3 药代动力学图 10-2 扎那
Page 282 and 283:
2.5 疗效若在出现症状的 48
Page 284 and 285:
2.5.4 特殊情况特殊情况下
Page 286 and 287:
2.10 总结商品名: 乐感清 ®
Page 288 and 289:
5. Cox RJ, Mykkeltvedt E, Sjursen H
Page 290 and 291:
influenza in adolescents and adults
Page 292 and 293:
and sialic acid, the viral receptor
Page 294 and 295:
3.2 结构目前,在多数国家
Page 296 and 297:
胺都不应在季节性和全国
Page 298 and 299:
3.8.2 儿童在美国,金刚乙胺
Page 300 and 301:
6. Bui M, Whittaker G, Helenius A.
Page 302 and 303:
19.Hayden FG, Belshe RB, Clover RD,
Page 304 and 305:
4.金刚烷胺金刚烷胺通过
Page 306 and 307:
报道较少(1~5%)的不良反应
Page 308 and 309:
在已知暴露后,应连续使用
Page 310 and 311:
在 15~30°C (59~86°F)保存金刚
Page 312 and 313:
12.Jefferson T, Deeks JJ, Demicheli
show all

2006流感报告 - Influenza Report

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?